Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Bevacizumab + MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 in combination with Avastin (bevacizumab) resulted in objective response (OS) in 7% (2/27) and stable disease (SD) in 37% (10/27) of patients with advanced solid tumors, with a median progression-free survival (mPFS) of 2.0 months in the Q2W (treatment every 2 weeks) arm, and OS in 6% (1/16), SD in 69% (11/16) of patients with a mPFS of 11.4 months in the Q3W arm (PMID: 29559563; NCT01248949).||29559563|